HAEMONETICS CORP — Director's Dealing 2020

Dec 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2020-12-10

Reporting Person: Simon, Christopher (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-10	Common Stock	G	194369	—	Disposed	170941	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-qualified Stock Option (Right to Buy)	$28.615	2023-06-29	Common Stock (196746)	196746	Direct
Non-qualified Stock Option (Right to Buy)	$41.64	2024-06-06	Common Stock (104516)	104516	Direct
Non-qualified Stock Option (Right to Buy)	$93.52	2025-06-11	Common Stock (40443)	40443	Direct
Non-qualified Stock Option (Right to Buy)	$98.025	2026-05-14	Common Stock (48971)	48971	Direct
Non-qualified Stock Option (Right to Buy)	$103.37	2027-05-18	Common Stock (49105)	49105	Direct

Footnotes

F1: These securities were transferred by the reporting person as a gift without any consideration to the Simon Family 2020 Irrevocable Trust for the benefit of the reporting person's children, which trust has an independent trustee.

F2: This number includes unvested restricted stock units previously reported.

F3: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.